DVM
ACOR

Dreman Value Management’s Acorda Therapeutics ACOR Stock Holding History

Dreman Value Management’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-13
Closed -$58K – 518
2014
Q1 		$58K Buy
13
+4
+44% +$16.2K ﹤0.01% 349
2013
Q4 		$30K Buy
+9
New +$35.1K ﹤0.01% 412

Other funds holding ACOR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return

Dreman Value Management's ACOR Position: Q2 2014 in Review

Dreman Value Management sold out of Acorda Therapeutics (ACOR) in Q2 2014, closing a stake of 13 shares — an estimated $58K sold.

Dreman Value Management first reported a position in ACOR in Q4 2013 and held it in 2 quarters. The position peaked at $58K in Q1 2014. 162 funds tracked by Wall St. Rank hold ACOR as of Q2 2014.

  • Dreman Value Management reported no remaining Acorda Therapeutics position as of Q2 2014 after selling out during the quarter.
  • Dreman Value Management sold 13 Acorda Therapeutics shares in Q2 2014, an estimated $58K.
  • Dreman Value Management first reported a position in Acorda Therapeutics in Q4 2013 and held it in 2 quarters.
  • Dreman Value Management's Acorda Therapeutics position peaked at $58K in Q1 2014.
  • 162 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q2 2014.

Based on Dreman Value Management's 13F filing for Q2 2014, filed 14 Aug 2014.